Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Sensus Healthcare (SRTS) over the last 9 years, with Q1 2025 value amounting to -$300000.0.

  • Sensus Healthcare's Cash from Financing Activities changed N/A to -$300000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$272000.0, marking a year-over-year decrease of 25789.47%. This contributed to the annual value of $15000.0 for FY2024, which is 13750.0% up from last year.
  • As of Q1 2025, Sensus Healthcare's Cash from Financing Activities stood at -$300000.0.
  • Sensus Healthcare's Cash from Financing Activities' 5-year high stood at $273000.0 during Q1 2022, with a 5-year trough of -$1.9 million in Q4 2022.
  • For the 5-year period, Sensus Healthcare's Cash from Financing Activities averaged around -$214357.1, with its median value being -$46500.0 (2021).
  • Over the last 5 years, Sensus Healthcare's Cash from Financing Activities had its largest YoY gain of 55500.0% in 2022, and its largest YoY loss of 348148.15% in 2022.
  • Over the past 5 years, Sensus Healthcare's Cash from Financing Activities (Quarter) stood at -$54000.0 in 2021, then tumbled by 3481.48% to -$1.9 million in 2022, then soared by 99.64% to -$7000.0 in 2023, then skyrocketed by 500.0% to $28000.0 in 2024, then plummeted by 1171.43% to -$300000.0 in 2025.
  • Its Cash from Financing Activities stands at -$300000.0 for Q1 2025, versus $28000.0 for Q4 2024 and -$30000.0 for Q3 2024.